Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.
Prostate cancer (CaP) is the second leading cause of cancer death in American men. Androgen deprivation therapy is initially effective in CaP treatment, but CaP recurs despite castrate levels of circulating androgen. Continued expression of the androgen receptor (AR) and its ligands has been linked...
Main Authors: | Mark A Titus, Brian Zeithaml, Boris Kantor, Xiangping Li, Karin Haack, Dominic T Moore, Elizabeth M Wilson, James L Mohler, Tal Kafri |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3260230?pdf=render |
Similar Items
-
Intracrine regulation of androgen receptor in prostate cancer
by: Dillard, Paulette Rawley
Published: (2010) -
Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
by: Lin Hui-Ping, et al.
Published: (2011-08-01) -
Genistein Combined Polysaccharide (GCP) Can Inhibit Intracrine Androgen Synthesis in Prostate Cancer Cells
by: Neelu Batra, et al.
Published: (2020-08-01) -
Inhibition of androgen receptor by decoy molecules delays progression to castration-recurrent prostate cancer.
by: Jae-Kyung Myung, et al.
Published: (2017-01-01) -
Identifying mechanisms of androgen receptor variant regulation in models of castrate resistant prostate cancer
by: Jones, Dominic Louis
Published: (2016)